Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 11/25 11:30:01 am
80.98 CHF   +0.88%
09:56aNOVARTIS : Genmab Announces Enapotamab Vedotin Update
AQ
08:01aNOVARTIS AG : Bryan Garnier maintains a Buy rating
MD
06:06aNOVARTIS AG : UBS reiterates its Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : The underlying trend is in force again

11/11/2019 | 03:33am EST
11/11/2019 | 03:33am EST
long trade
Target price hit
Entry price : 88.6CHF | Target : 92.7CHF | Stop-loss : 85.9CHF | Potential : 4.63%
Novartis's shares display attractive technical aspects to anticipate a comeback of the underlying trend.
Investors have an opportunity to buy the stock and target the CHF 92.7.
Novartis : Novartis : The underlying trend is in force again
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.

Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the past twelve months, EPS forecast has been revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The tendency within the weekly time frame is positive above the technical support level at 82.25 CHF

Weaknesses
  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The group usually releases earnings worse than estimated.
  • With an enterprise value anticipated at 4.49 times the sales for the current fiscal year, the company turns out to be overvalued.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

© Zonebourse.com 2019
Stocks mentioned in the article
ChangeLast1st jan.
AT HOME GROUP INC. 4.78% 18.85 Delayed Quote.227.09%
JUST GROUP PLC -3.57% 58 Delayed Quote.-23.86%
NOVARTIS AG 0.88% 80.98 Delayed Quote.-12.66%
WILL GROUP, INC. 1.02% 990 End-of-day quote.-20.93%

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 49 435 M - -
Net income 2020 8 326 M - -
Net Debt 2020 19 268 M - -
P/E ratio 2020 22,1x
Yield 2020 3,90%
Capitalization 184 B 203 B -
EV / Sales 2020 4,12x
EV / Sales 2021 3,79x
Nbr of Employees 110 000
Free-Float 86,9%
Upcoming event on NOVARTIS AG
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 105,79 $
Last Close Price 80,98 $
Spread / Highest target 73,9%
Spread / Average Target 30,6%
Spread / Lowest Target -20,1%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-12.66%200 273
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-6.59%203 437
MERCK & CO., INC.-11.89%202 757
ABBVIE INC.17.42%183 539